All staff who can work at home should continue to do so. Only with an explicit request from a supervisor should a staff member return to campus. For more information, review COVID-19 Workplace Guidance.
Yale RIDC - Yale University Radioactive Investigational Drug Committee
The Yale University Radioactive Investigational Drug Committee (Yale RIDC) is Yale University mandated committee. All human subject research protocols involving the use of investigational radioactive drugs with an IND, amended IND, or an FDA allowed IND exemption (as well as the use of FDA-approved radiopharmaceuticals) must be reviewed and approved by the YU RIDC. The research that requires YU RIDC review is typically conducted at the Yale University PET Center under Yale University’s NRC medical use license. Subject to the IRB final approval, the YU RIDC, has the authority to approve, disapprove or require modifications to the protocol as it relates to the use of radiopharmaceuticals in human subjects for research.